195 related articles for article (PubMed ID: 21641953)
1. Vaccine adjuvant activity of 3M-052: an imidazoquinoline designed for local activity without systemic cytokine induction.
Smirnov D; Schmidt JJ; Capecchi JT; Wightman PD
Vaccine; 2011 Jul; 29(33):5434-42. PubMed ID: 21641953
[TBL] [Abstract][Full Text] [Related]
2. Intranasal c-di-GMP-adjuvanted plant-derived H5 influenza vaccine induces multifunctional Th1 CD4+ cells and strong mucosal and systemic antibody responses in mice.
Madhun AS; Haaheim LR; Nøstbakken JK; Ebensen T; Chichester J; Yusibov V; Guzman CA; Cox RJ
Vaccine; 2011 Jul; 29(31):4973-82. PubMed ID: 21600260
[TBL] [Abstract][Full Text] [Related]
3. Induction of a potent immune response in the elderly using the TLR-5 agonist, flagellin, with a recombinant hemagglutinin influenza-flagellin fusion vaccine (VAX125, STF2.HA1 SI).
Taylor DN; Treanor JJ; Strout C; Johnson C; Fitzgerald T; Kavita U; Ozer K; Tussey L; Shaw A
Vaccine; 2011 Jul; 29(31):4897-902. PubMed ID: 21596084
[TBL] [Abstract][Full Text] [Related]
4. Immunogenicity, protective efficacy and mechanism of novel CCS adjuvanted influenza vaccine.
Even-Or O; Samira S; Rochlin E; Balasingam S; Mann AJ; Lambkin-Williams R; Spira J; Goldwaser I; Ellis R; Barenholz Y
Vaccine; 2010 Sep; 28(39):6527-41. PubMed ID: 20412874
[TBL] [Abstract][Full Text] [Related]
5. Synthetic double-stranded RNA poly(I:C) combined with mucosal vaccine protects against influenza virus infection.
Ichinohe T; Watanabe I; Ito S; Fujii H; Moriyama M; Tamura S; Takahashi H; Sawa H; Chiba J; Kurata T; Sata T; Hasegawa H
J Virol; 2005 Mar; 79(5):2910-9. PubMed ID: 15709010
[TBL] [Abstract][Full Text] [Related]
6. A new intranasal influenza vaccine based on a novel polycationic lipid--ceramide carbamoyl-spermine (CCS) I. Immunogenicity and efficacy studies in mice.
Joseph A; Itskovitz-Cooper N; Samira S; Flasterstein O; Eliyahu H; Simberg D; Goldwaser I; Barenholz Y; Kedar E
Vaccine; 2006 May; 24(18):3990-4006. PubMed ID: 16516356
[TBL] [Abstract][Full Text] [Related]
7. An α-GalCer analogue with branched acyl chain enhances protective immune responses in a nasal influenza vaccine.
Lee YS; Lee KA; Lee JY; Kang MH; Song YC; Baek DJ; Kim S; Kang CY
Vaccine; 2011 Jan; 29(3):417-25. PubMed ID: 21087689
[TBL] [Abstract][Full Text] [Related]
8. Induction of cross-protective immunity against influenza A virus H5N1 by an intranasal vaccine with extracts of mushroom mycelia.
Ichinohe T; Ainai A; Nakamura T; Akiyama Y; Maeyama J; Odagiri T; Tashiro M; Takahashi H; Sawa H; Tamura S; Chiba J; Kurata T; Sata T; Hasegawa H
J Med Virol; 2010 Jan; 82(1):128-37. PubMed ID: 19950232
[TBL] [Abstract][Full Text] [Related]
9. The virus-induced signaling adaptor molecule enhances DNA-raised immune protection against H5N1 influenza virus infection in mice.
Luo M; Qu X; Pan R; Zhu D; Zhang Y; Wu J; Pan Z
Vaccine; 2011 Mar; 29(14):2561-7. PubMed ID: 21303708
[TBL] [Abstract][Full Text] [Related]
10. Reverse micelle-encapsulated recombinant baculovirus as an oral vaccine against H5N1 infection in mice.
Prabakaran M; Madhan S; Prabhu N; Geng GY; New R; Kwang J
Antiviral Res; 2010 May; 86(2):180-7. PubMed ID: 20153776
[TBL] [Abstract][Full Text] [Related]
11. Heterosubtypic immunity to influenza mediated by liposome adjuvanted H5N1 recombinant protein vaccines.
Thueng-in K; Maneewatch S; Srimanote P; Songserm T; Tapchaisri P; Sookrung N; Tongtawe P; Channarong S; Chaicumpa W
Vaccine; 2010 Sep; 28(41):6765-77. PubMed ID: 20688037
[TBL] [Abstract][Full Text] [Related]
12. Protective effect of nasal immunization of influenza virus hemagglutinin with recombinant cholera toxin B subunit as a mucosal adjuvant in mice.
Isaka M; Zhao Y; Nobusawa E; Nakajima S; Nakajima K; Yasuda Y; Matsui H; Hasegawa T; Maeyama J; Morokuma K; Ohkuma K; Tochikubo K
Microbiol Immunol; 2008 Feb; 52(2):55-63. PubMed ID: 18380802
[TBL] [Abstract][Full Text] [Related]
13. Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant.
Prabakaran M; Velumani S; He F; Karuppannan AK; Geng GY; Yin LK; Kwang J
Virology; 2008 Oct; 380(2):412-20. PubMed ID: 18786689
[TBL] [Abstract][Full Text] [Related]
14. Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin.
Bright RA; Carter DM; Daniluk S; Toapanta FR; Ahmad A; Gavrilov V; Massare M; Pushko P; Mytle N; Rowe T; Smith G; Ross TM
Vaccine; 2007 May; 25(19):3871-8. PubMed ID: 17337102
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant effect of Bacillus firmus on the expression of cytokines and toll-like receptors in mouse nasopharynx-associated lymphoid tissue (NALT) after intranasal immunization with inactivated influenza virus type A.
Zanvit P; Tichopád A; Havlíčková M; Novotná O; Jirkovská M; Kološtová K; Cechová D; Julák J; Sterzl I; Prokešová L
Immunol Lett; 2010 Nov; 134(1):26-34. PubMed ID: 20709105
[TBL] [Abstract][Full Text] [Related]
16. Zymosan enhances the mucosal adjuvant activity of poly(I:C) in a nasal influenza vaccine.
Ainai A; Ichinohe T; Tamura S; Kurata T; Sata T; Tashiro M; Hasegawa H
J Med Virol; 2010 Mar; 82(3):476-84. PubMed ID: 20087927
[TBL] [Abstract][Full Text] [Related]
17. Complete protection against a H5N2 avian influenza virus by a DNA vaccine expressing a fusion protein of H1N1 HA and M2e.
Park KS; Seo YB; Lee JY; Im SJ; Seo SH; Song MS; Choi YK; Sung YC
Vaccine; 2011 Jul; 29(33):5481-7. PubMed ID: 21664216
[TBL] [Abstract][Full Text] [Related]
18. Influenza hemagglutinin vaccine with poly(gamma-glutamic acid) nanoparticles enhances the protection against influenza virus infection through both humoral and cell-mediated immunity.
Okamoto S; Yoshii H; Akagi T; Akashi M; Ishikawa T; Okuno Y; Takahashi M; Yamanishi K; Mori Y
Vaccine; 2007 Nov; 25(49):8270-8. PubMed ID: 17977633
[TBL] [Abstract][Full Text] [Related]
19. Poly(gamma-glutamic acid) nano-particles combined with mucosal influenza virus hemagglutinin vaccine protects against influenza virus infection in mice.
Okamoto S; Matsuura M; Akagi T; Akashi M; Tanimoto T; Ishikawa T; Takahashi M; Yamanishi K; Mori Y
Vaccine; 2009 Sep; 27(42):5896-905. PubMed ID: 19647814
[TBL] [Abstract][Full Text] [Related]
20. Influenza antigen-sparing by immune stimulation with Gram-positive enhancer matrix (GEM) particles.
Saluja V; Visser MR; Ter Veer W; van Roosmalen ML; Leenhouts K; Hinrichs WL; Huckriede A; Frijlink HW
Vaccine; 2010 Nov; 28(50):7963-9. PubMed ID: 20946860
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]